The burgeoning landscape of medication for obesity and type 2 metabolic disorder is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and https://craigiteo868530.blog5star.com/39306106/retatrutide-vs-tirzepatide-a-comparative-analysis